Laboratorios Richmond SACIF

Laboratorios Richmond SACIF EPS

The Earnings per Share (EPS) of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 295.29 ARS. In the previous year, Earnings per Share (EPS) was -134.37 ARS — a change of -319.75% (higher).

EPS

295.29ARS

YoY

-319.75%

Last updated:

Earnings per Share (EPS) of Laboratorios Richmond SACIF is 2024 295.29 ARS. Earnings per Share (EPS) of Laboratorios Richmond SACIF was 2023 -134.37 ARS. It decreases by -319.75% higher compared to the previous year.

The Laboratorios Richmond SACIF EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2017
0.60 ARS
Jan 1, 2018
-4.11 ARS
Jan 1, 2019
1.96 ARS
Jan 1, 2020
9.09 ARS
Jan 1, 2021
14.27 ARS
Jan 1, 2022
2.02 ARS
Jan 1, 2023
-134.37 ARS
Jan 1, 2024
295.29 ARS
The Laboratorios Richmond SACIF EPS history
YEAREPSYoY
295.29ARS-319.75%
-134.37ARS-6,739.39%
2.02ARS-85.81%
14.27ARS+56.98%
9.09ARS+362.98%
1.96ARS-147.80%
-4.11ARS-780.85%
0.60ARS-57.63%
1.42ARS+1,527.05%
0.09ARS-9.93%
0.10ARS+6,370.03%
0.00ARS-97.56%
0.06ARS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

Earnings per Share (EPS) of Laboratorios Richmond SACIF is 295.29 ARS in 2024.

Earnings per Share (EPS) of Laboratorios Richmond SACIF changed from -134.37 ARS to 295.29 ARS, representing a -319.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF